Long-term Safety Study of Emraclidine for Adults with Schizophrenia
- Substances:Emraclidine
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Emraclidine
- Sponsor:Cerevel Therapeutics LLC
Rare diseases
Investigational molecules
Locations
Back to Bulgaria40 clinical trials in Pazardzhik, Bulgaria. Every trial is listed in the EU Clinical Trials Register and updated daily.
Bulgaria
Bulgaria
Bulgaria
BulgariaThe busiest research cities in the country
What the registry says about research in the country
Clinical research focusing on innovative treatments for chronic obstructive pulmonary disease (COPD) and asthma, evaluating new therapeutic approaches and medications to improve patient outcomes.
Multiple trials are exploring both established and novel therapeutic options for patients with moderate to severe respiratory conditions.
Groundbreaking research in multiple sclerosis and seizure management, with trials evaluating new therapeutic agents and treatment approaches for various neurological conditions.
Studies are investigating both progressive and relapsing forms of neurological conditions to develop more effective treatments.
Innovative research targeting heart failure and stroke prevention, including studies on new medications for atrial fibrillation and post-stroke care.
These trials aim to improve cardiovascular outcomes and reduce the risk of serious complications in high-risk patients.
Advanced research in schizophrenia and Alzheimer's disease psychosis, focusing on novel therapeutic approaches and long-term treatment solutions.
Trials are exploring new therapeutic options to address both acute symptoms and long-term disease management.
Tell us about your condition – we search every trial in Europe and connect you with the right site.